Business
Publication of New Research
Publication of New Research.
About this update from Bsf Enterprise Plc
[{"type":"text","content":"\n\n1 June 2023\n \nBSF Enterprise PLC\n(\"BSF\" or the \"Company\")\n \nPublication of New Research\nBSF (LSE: BSFA; OTCQB: BSFAF), the Main Market listed biotech company and the owner of pioneering UK-based clinical and cellular agriculture company 3D Bio-Tissues, is pleased to inform shareholders that a new research note on the Company has recently been published by Shard Capital Partners LLP.\nThe note can be found on the Company's website, www.bsfenterprise.com, or via the Shard Portal.\n \n-Ends-\n \nFor further enquiries, please visit www.bsfenterprise.com or contact:\n\n\n\n \n \nBSF Enterprise PLC\n\n\n \n \nVia SEC Newgate below\n\n\n\n\nChe Connon - CEO & Executive Director\nGeoff Baker - Executive Director\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nShard Capital (Broker)\n\n\n\n\n\n\n\nDamon Heath\nIsabella Pierre\n\n\n0203 971 7000\n0207 1869 927\n\n\n\n\n\n\n\n\n\n\n\n\n \nSEC Newgate (Financial Communications)\n\n\n\n\n\n\n\nBob Huxford\nElisabeth Cowell\nGeorge Esmond\n\n\n020 3757 6882\[email protected]\n\n\n\n\n \nISIN of the Ordinary Shares is GB00BHNBDQ51\nSEDOL Code is BHNBDQ5.\n \nNotes to Editors\nBSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors.\n \nIt owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas to help restore vision to millions of people. Building on this success, it has produced the UK's first high quality lab-grown meat from its laboratory using its technology.\n \nBSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as acquiring complementary businesses. It aims to acquire a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale. \n \n\n","length":6199,"tagName":"div"}]